Cyclic Acetal-Based Lipid Nanoparticles Deliver mRNA In Vivo for Tumor Immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Nanomedicine

Background:

• Lipid nanoparticle (LNP)-mRNA technology faces challenges in tumor immunotherapy, including inefficient mRNA delivery, limited targeted protein expression, and suboptimal innate immunogenicity.
• Developing effective and safe mRNA delivery systems is crucial for advancing cancer immunotherapy.

Purpose of the Study:

• To screen and develop novel cyclic acetal-based ionizable lipid nanoparticles (LNPs) for enhanced mRNA delivery and tumor immunotherapy.
• To evaluate the efficacy and safety of these new LNP formulations in vitro and in vivo.

Main Methods:

• Screening of 16 cyclic acetal-based ionizable lipid nanoparticles using in vitro and in vivo assays.
• Incorporation of a cyclic acetal-based adjuvant lipid (YK-TLR-001) into optimized LNP formulations (YK-712 and YK-716).
• Assessment of mRNA expression, antigen-presenting cell (APC) maturation, antigen presentation, cellular immunogenicity, and tumor growth inhibition in animal models.

Main Results:

• Two optimized LNP formulations, YK-712 and YK-716, demonstrated enhanced mRNA expression in the spleen.
• These formulations effectively induced antigen-presenting cell (APC) maturation and promoted antigen presentation.
• Animal studies showed activated cellular immunogenicity in healthy mice and significant inhibition of tumor growth in the B16F10 melanoma model.

Conclusions:

• Cyclic acetal-based LNPs, particularly when incorporating YK-TLR-001, represent a promising platform for mRNA tumor immunotherapy.
• These novel lipid nanoparticles (LNPs) offer improved mRNA delivery, enhanced immune responses, and effective tumor growth inhibition.
• This research provides a new direction for designing advanced mRNA vectors for cancer treatment.